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Abstract
Objective The aim of this study was to characterise the
population pharmacokinetics of FE 999049, a novel
recombinant human follicle-stimulating hormone (FSH),
after multiple dosing in healthy women, taking into
account endogenous FSH levels and the reproductive hor-
mone dynamics.
Methods Longitudinal measurements of FSH, luteinising
hormone, progesterone, estradiol, and inhibin B levels were
collected after repeated subcutaneous dosing with 225 IU
of FE 999049 in 24 gonadotropin downregulated healthy
women. The FSH data were described using nonlinear
mixed-effects modelling.
Results The measured FSH levels were modelled as a
sum of endogenous FSH and FE 999049. The FE 999049
population pharmacokinetics were best described using a
one-compartment model with first-order absorption and
elimination, and a transit model for delayed absorption.
The apparent clearance and volume of distribution
increased with body weight in accordance with an allo-
metrically scaled power exponent of 0.75 and 1, respec-
tively. Endogenous FSH levels were lower in individuals
with higher progesterone levels at baseline and were fur-
ther suppressed over time with increasing inhibin B levels.
Conclusions This characterisation of FE 999049 popula-
tion pharmacokinetics after repeated dosing is in line with
previous findings after single-dose administration. The
results provide a basis for study design and data evaluation
in the future development of recombinant FSH products,
and show it can be of importance to account for endoge-
nous FSH levels and its variation over time for accurate
estimation of exogenously administered FSH pharmacoki-
netic parameters. Thus, correcting FSH concentrations by
the observed endogenous FSH baseline value at all time
points may be incorrect.
Key Points
The multiple-dose pharmacokinetics of FE 999049
have been described, accounting for endogenous
follicle-stimulating hormone (FSH) levels.
Exposure to FE 999049 was influenced by body
weight, which may be a potential factor for
individualised dosing recommendations.
Endogenous FSH levels were influenced by
progesterone and inhibin B levels. This time-varying
contribution of endogenous FSH may be important to
consider when characterising the pharmacokinetics
of recombinant FSH products.
1 Introduction
Follicle-stimulating hormone (FSH) is a gonadotropin that
is synthesised and secreted by the anterior pituitary gland.
The major function of FSH is to regulate the reproductive
processes by stimulating the gonads. In females, FSH
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stimulates follicular development in the ovaries and pro-
duction of inhibin B, progesterone, and oestrogens by the
ovarian follicular granulosa cells. Luteinising hormone
(LH), another gonadotropin from the anterior pituitary,
stimulates the theca cells of the follicles to deliver andro-
gens to the granulosa cells for conversion to oestrogens. It
is also responsible for ovulation of the dominant follicle
that has reached a fully mature, pre-ovulatory stage. The
ovarian hormones promote further follicular development
as well as exerting negative and positive feedback loops to
the hypothalamus and pituitary affecting the gonadotropin
production and secretion. In addition, gonadotropin secre-
tion is stimulated by gonadotropin-releasing hormone
(GnRH) produced in the hypothalamus.
Female infertility can be caused by numerous factors at
any level, from the hypothalamus to the ovaries and
uterus. Gonadotropin therapy with either menotropins or
recombinant FSH (rFSH) preparations can be used for
infertility treatment when the cause is not primary ovarian
failure, such that the ovaries are still responsive and
contain primordial follicles. The purpose of controlled
ovarian stimulation with daily administration of gonado-
tropins prior to assisted reproductive technologies such as
in vitro fertilisation (IVF) or intracytoplasmic sperm
injection (ICSI) is to obtain an adequate number of
oocytes per retrieval, with minimum risks for the patient
[1]. An appropriate ovarian response leading to the
availability of several embryos makes it possible to select
the best one(s) for transfer.
Recently, a novel recombinant human FSH (rhFSH;
FE 999049, Ferring Pharmaceuticals A/S) was expressed
for the first time in a human cell line (PER.C6; Crucell,
Leiden, The Netherlands), while existing rFSH prepa-
rations in clinical use (e.g. follitropin-a and follitropin-
b) are derived from Chinese hamster ovary cell lines
(CHO). Previously, in a population pharmacokinetic
analysis of first-in-human data after single ascending
doses [2], body weight was identified as a factor that
negatively correlates with serum FE 999049 concentra-
tion. In the present work, the FE 999049 population
pharmacokinetics were characterised after multiple
dosing. The influence of body weight on drug exposure
was investigated in order to further explore its impor-
tance as a factor for individualised FE 999049 dosing.
Moreover, endogenous FSH levels may vary over time
across the target patient group of infertile women, which
may be an important aspect to consider in rFSH drug
development and when analysing hormone data. The
endogenous FSH contribution to the total FSH levels,
and the influence of other reproductive hormones on the
endogenous FSH levels, were therefore also evaluated in
this analysis.
2 Methods
2.1 Clinical Trial Design and Data
Data were generated in a randomised, double-blind, active
control, multiple-dose trial with the aim of investigating the
safety, tolerability, immunogenicity, pharmacokinetics, and
pharmacodynamics of FE 999049 in healthy women. The
trial was performed according to the Helsinki declaration
and good clinical practice, and was approved by regulatory
authorities and local Ethics Committees. All subjects gave
written informed consent to participate. The trial has been
described in more detail in a recent publication comparing
the pharmacokinetic and pharmacodynamic properties of
FE 999049 and GONAL-F (follitropin-a; EMD Serono,
Inc., Rockland, USA) using non-compartmental analysis
(NCA) [3]. Briefly, 49 healthy women were administered
daily subcutaneous doses of 225 IU rFSH for 7 days; 24 of
the 49 women were treated with FE 999049 and 25 women
received GONAL-F as an active comparator. Prior to the
trial (day -28 and -14), subjects were administered two
doses of a GnRH agonist (LUPRON DEPOT, 1-month
depot) to downregulate endogenous FSH.
Blood samples for FSH, inhibin B, estradiol, proges-
terone, and LH measurements were collected at 60 and
30 min prior to administration of FE 999049, immediately
before administration, and once daily for 15 days. In
addition, after administration of the last dose on day 6 and
until day 8, the FSH concentration was measured every
4 h. Analysis of serum FSH concentrations was performed
at Ferring Pharmaceuticals A/S using a validated
immunoassay based on electrochemiluminescence (MSD
sectorTM Imager 2400) with a lower limit of quantification
(LLOQ) of 0.075 lg/L.
The present analysis included data from the 24 women
receiving FE 999049. Three of the 672 FSH measurements
(0.4 %) were below the quantification limit and were
excluded from further analysis. The personal demographics
and baseline characteristics for the included subjects are
listed in Table 1. Subjects with missing hormone baseline
values were given the median population baseline value.
Between days 6 and 8, FSH was measured every 4 h, and
the other hormones were measured only once daily, leaving
missing hormone values in between. To fill out the extra
time points, the last measured hormone values were carried
forward.
2.2 Pharmacokinetic Modelling
The pharmacokinetic model was developed using nonlinear
mixed-effects modelling, where both the population
parameters, interindividual variability (IIV), and residual
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errors are estimated. For parameters with IIV, the ith
subject’s individual parameter (hi) is log-normally
distributed:
hi ¼ h exp gið Þ ð1Þ
where h is the typical population parameter and gi is the
individual random effect from an approximately normal
distribution with mean zero and variance x2 for describing
the IIV of the parameter. In the model, potential influential
factors can be tested for significance as a covariate to
explain some of the IIV in a parameter. Thus, the set of
individual parameters (Hi) is given as a function of the
typical population parameters (H) individual values of the
covariates (ci) and random effects (gi):
Hi ¼ g H; ci; gið Þ ð2Þ
The residual errors (e) are assumed normally distributed
with mean zero and variance r2, and are the unexplained
deviations of model predictions from the observations:
yij ¼ f tij;Hi
 þ eij ð3Þ
where yij is the observation at time tij and the subscript ij
denotes the jth number for subject i. The individual model
prediction f () at time tij is calculated from the individual
parameters (Hi).
Model development was guided by changes in the
NONMEM objective function value (OFV), precision of
parameter estimates, and graphical model goodness-of-fit
assessments, including visual predictive checks (VPC). In
the VPC, the observed data are compared with model
predictions based on 1000 simulated trial datasets using the
final model. It displays the observations and the 2.5th, 50th,
and 97.5th percentiles of observations, and the 95 % con-
fidence intervals (CI) for the corresponding model predic-
tions are plotted. The OFV is approximately proportional to
-2log likelihood. The difference in OFV (dOFV) between
two nested models is approximately Chi square-distributed,
with degrees of freedom (df) equal to the difference in the
number of parameters. Based on this, the statistical sig-
nificance for inclusion/exclusion of a model parameter can
be judged. A significance level of 0.05 was used for dis-
crimination among nested models and covariate testing,
corresponding to a 3.84 change in OFV for 1 df.
Measurable FSH levels before drug administration
indicated that endogenous FSH was not fully suppressed in
this trial. The total FSH amount at time t in the central
compartment was therefore modelled as the sum of the
endogenous FSH and the exogenously administered rhFSH
(FE 999049):
FSHðtÞ ¼ FSHen tð Þ + rhFSH tð Þ ð4Þ
The endogenous FSH was assumed to have the same
elimination rate constant from the central compartment as
FE 999049; thus, the total FSH is eliminated from the
central compartment with rate constant k given by
clearance (CL) divided by volume of distribution (V).
Since data are obtained after subcutaneous dosing, the
bioavailability (F) is not known. The CL and V estimated
here are therefore the apparent CL (CL/F) and apparent V
(V/F).
The change in endogenous FSH amount over time in the
central compartment was described as a turnover model
with a zero-order production rate kin:
dFSHen tð Þ
dt
¼ kin  k  FSHen tð Þ ð5Þ
At time zero, before rhFSH dosing, the measured
concentration in the central compartment is purely
endogenous FSH. The endogenous FSH baseline
concentrations (FSHbl) for each subject can therefore be
estimated as the initial concentration in the central
compartment and is the initial condition for the
differential equation for the central compartment
FSHblV/F, i.e. the individual endogenous FSH amount at
baseline. When assuming steady state and hence zero
change in the total FSH concentration before dosing,
individual values of kin can be calculated from the other
estimated parameters and baseline values.
One- and two-compartment models were tested for
describing the distribution of FE 999049. A lag-time and
transit compartments were investigated for modelling a
potential delay in the absorption process. Body weight, age,
and hormone (estradiol, inhibin B, progesterone) values at
baseline were tested as potential covariates, explaining
some of the IIV in parameter estimates. Inhibin B was also
tested as a covariate over time since it has a purely inhi-
bitory effect on FSH. The measured hormone levels were
assumed to not affect the rhFSH concentration, but only
Table 1 Summary of subject characteristics
Mean (Range)
Age (years) 31.1 (21.5–38.7)
Height (cm) 163.5 (149.0–175.3)
Weight (kg) 71.5 (46.1–86.6)
BMI (kg/m2) 26.6 (20.8–28.9)
FSH (lg/L) 0.211 (0.089–0.376)
E2 (pg/mL) 24.21 (7.0–55.0)
LH (IU/L) 0.719 (0.1–1.4)
Prog (lg/L) 0.652 (0.08–1.49)
InhB (pg/mL) 22.0 (4.0–89.0)
Demographics and measured baseline hormone levels for the 24
subjects receiving FE 999049
BMI body mass index, FSH follicle-stimulating hormone, E2 estra-
diol, LH luteinising hormone, Prog progesterone, InhB inhibin B
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tested as covariates on the endogenous FSH baseline
parameter (FSHbl). Besides a decrease in OFV, the sig-
nificance of a covariate was also evaluated by looking at
the reduction in the IIV, measured as a coefficient of
variation (CV) for the parameter’s random effect.
2.3 Software
The models were implemented and parameters estimated in
NONMEM 7.2.0 (Icon Development Solutions, Ellicott
City, MD, USA) [4]. Data handling and graphical repre-
sentations were performed in R version 2.11.1 [5]. VPCs
were performed using PsN [6, 7] and plotted using Xpose
[8].
3 Results
The best structural model was a one-compartment distri-
bution model. The FE 999049 absorption was found to be
delayed, and a one-compartment transit model best
described the process. Endogenous FSH contributed sig-
nificantly to the total FSH concentration in the central
compartment. Observed inhibin B levels [InhB(t)] sup-
pressed endogenous FSH production rate (kin) over time
when introduced in the model as a time-varying covariate.
The relationship was found to be best described by an
inhibitory Emax model, also know as an Imax function,
expressed as a fractional inhibition with complete inhibi-
tion possible and a parameter InhBef as the inhibin B
concentration giving 50 % inhibition [see Eq. (8)].
The full compartment model is illustrated in Fig. 1 and
the corresponding differential equations are as follows:
drhFSHDS tð Þ
dt
¼ ktr  rhFSHDS tð Þ ð6Þ
drhFSHTR tð Þ
dt
¼ ktr  rhFSHDS tð Þ  ka  rhFSHTR tð Þ ð7Þ
dFSH tð Þ
dt




 rhFSHTR tð Þ  k  FSH tð Þ ð8Þ
where rhFSHDS(t) and rhFSHTR(t) are the FE 999049
amounts at the dosing site and in the transit compartment,
respectively, and ktr is the absorption rate from the dosing
site to the transit compartment. Equation (8) describes the
change in total FSH amount in the central compartment,
with the endogenous FSH contribution as the first term.
The exogenously administered rhFSH enters the central
compartment with rate constant ka.
IIV was introduced for CL/F, V/F, ktr, and FSHbl. The
variances of the IIV on CL/F and V/F were positively
correlated. Body weight was an allometrically scaled
covariate at CL/F and V/F, with the power exponents fixed
to 0.75 and 1, respectively. Adding body weight as a
covariate reduced CV for the unexplained IIV from 18.1 to
15.6 % CV for CL/F, and from 22.0 to 18.4 % CV for V/
F. A trend towards lower estimated FSH baseline levels
was seen in individuals with higher progesterone baseline
levels (Fig. 2). The progesterone baseline effect was con-
firmed to be a statistically significant covariate when
modelled as an inhibitory power function at the FSHbl
parameter. This decreased IIV in FSHbl from 32.6 to
27.8 % CV.
A combined additive and proportional error model was
used to describe the residual error. The final model
parameter estimates are displayed in Table 2. The VPC
plot (Fig. 3) based on 1000 simulations, shows that the
model overall adequately predicts the FSH concentrations
over time, with appropriate variation. The model also sat-
isfactorily predicted the individual pharmacokinetic profile
for each subject in the trial (Fig. 4). The typical population
CL/F and V/F for a 65-kg woman were 0.423 L/h and
24.3 L, respectively, giving an elimination rate of
0.017 h-1 and a terminal half-life of 40 h. When the best
Fig. 1 Compartment diagram illustrating the pharmacokinetic model
for FE 999049 with a contribution of endogenous FSH to the central
compartment. FSH follicle-stimulating hormone, rhFSH recombinant
human FSH, FSHen(t) endogenous FSH amount, InhB(t) inhibin B
level, rhFSHTR(t) rhFSH amount in the transit compartment, FSH(t)
total FSH amount in the central compartment, kin endogenous FSH
production rate, ktr absorption rate from the dosing site, ka absorption
rate from the transit compartment, k elimination rate
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model was found in a forward development process, it was
checked to see if all the elements were still significant or if
the model could be reduced. Table 3 describes the resulting
increase in OFV after removing the elements. No reduction
was possible since the dOFV was a minimum of 7 and up
to 78.
In order to see what difference accounting for endoge-
nous FSH in the model makes, the individual concentra-
tion–time profiles for the model-predicted endogenous FSH
level were compared with when the observed endogenous
FSH baseline was assumed to be constant throughout the
trial (Fig. 5). Due to the suppression by observed
InhB(t) over time, the predicted endogenous FSH levels
were lower than the observed baselines. Furthermore,
accounting for inhibin B suppression of the endogenous
FSH contribution over time increased the V/F estimate
from 18.9 to 24.3 L. Not including inhibin B as a covariate
in the final model resulted in an increase from 83.4 to
164.9 % CV at ktr.
4 Discussion
The FE 999049 population pharmacokinetics have previ-
ously been characterised after single-dose administration
using a one-compartment model. The results were in
agreement with modelling results from the literature [2]. In
accordance with those results, the current analysis showed
that after multiple FE 999049 dosing, the population
pharmacokinetics were also best described by a one-com-
partment model with first-order elimination and absorption
through a transit compartment. A correlation between CL/
F and V/F was observed, and body weight was an allo-
metrically scaled covariate for both CL/F and V/F. Hereby,
it was confirmed that lower average steady-state drug
exposure in females correlates with higher body weight
after repeated doses, which is in agreement with single-
dose FE 999049 results.
In contrast to the single-dose trial, FSH downregulation
in this trial was not complete since a measurable endoge-
nous FSH level was detected before any drug administra-
tion. The observed endogenous FSH contributes to total
FSH measurements and thereby affects the evaluation of
rhFSH concentrations in the trial; thus, it had to be
accounted for in the model. To adjust the model accord-
ingly, it was necessary to add an endogenous supply of
FSH to the central compartment for proper prediction of
the total FSH concentration.
Fig. 2 The relationship between endogenous FSH and progesterone
at baseline. Points are individual-predicted FSHbl values and observed
progesterone baseline values with a smooth LOWESS trend line
(broken line). The solid line is the power function used in the model
describing the typical population relationship for the effect of
progesterone baseline at the parameter FSHbl. FSH follicle-stimulat-
ing hormone, FSHb1 endogenous FSH baseline
Table 2 Pharmacokinetic
parameter estimates
Parameter Estimate (RSE%) IIV CV% (RSE%) Shrinkage (%)
CL/F (L/h) 0.423 (3.9) 15.6 (12.7) -1.05
V/F (L) 24.30 (4.6) 18.4 (14.4) 2.80
ktr (h





0.162 (9.1) 27.8 (16.5) 5.51
Progblef -0.246 (34.7)
InhBef 100 (37.2)
Typical population parameter estimates obtained from modelling
For CL/F and V/F the value is the typical value for a woman weighing 65 kg
RSE relative standard error, IIV interindividual variability, CV coefficient of variation, F bioavailability,
CL/F apparent clearance, V/F apparent volume of distribution, ktr absorption rate from the dosing site, ka
absorption rate from the transit compartment, FSHbl endogenous follicle-stimulating hormone baseline,
Progblef power exponent for progesterone baseline covariate effect, InhBef inhibin B time-varying covariate
effect
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When evaluating the pharmacokinetics of drugs that are
naturally occurring substances, data are often baseline
corrected in order to get values representing only the
exogenously administered drug. However, when dealing
with hormones, fluctuations from the endogenous baseline
value over time may be observed due to various feedback
control systems. Even with gonadotropin downregulation,
the endogenous FSH level will most likely change over
time as progesterone, inhibin B, and estradiol exert inhi-
bitory and stimulatory feedback loops at the production and
release of gonadotropins. The potential impact of varying
endogenous FSH levels at the pharmacokinetic assessment
of FE 999049 was tested by incorporating different
covariate relationships in the model. Before any drug was
administered, there was a tendency towards a decreased
endogenous FSH baseline with increasing progesterone
baseline. A power function for the relation between pro-
gesterone baseline and FSHbl was shown to be significantly
better than using a linear, an exponential, or an Imax
function. When introduced as a time-varying covariate,
inhibin B was found to suppress the endogenous FSH
production rate over time, with an Imax function being the
Fig. 3 Visual predictive check for the final model, showing the
individual observed FSH concentrations (points) and the 2.5th, 50th,
and 97.5th percentiles of observations (lines). The shaded areas are
the 95 % confidence intervals for the 2.5th, 50th, and 97.5th
percentiles of the simulations. FSH follicle-stimulating hormone
Fig. 4 Individual model fit with
observed (points) and predicted
(lines) total FSH concentrations
versus time. The number at each
subplot is the subject
identification number. FSH
follicle-stimulating hormone
Table 3 Change in objective function value for reduced models
Removing df dOFV
WT at V/F 0 14.36
WT at CL/F 0 12.61
WT at CL/F and V/F 0 8.91
cov (CL/F, V/F) 1 11.77
Progesterone effect 1 7.01
Inhibin B effect 1 78.01
The resulting dOFV when removing covariates or the correlation
between CL/F and V/F [cov(CL/F,V/F)]
F bioavailability, CL/F apparent clearance, V/F apparent volume of
distribution, WT body weight, df degrees of freedom, dOFV differ-
ence in objective function value
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most significant relationship. When accounting for the
inhibitory effect of inhibin B over time, the resulting
model-predicted endogenous FSH concentration profiles
indicated that the observed FSH baseline is an overestimate
of the endogenous FSH level at all time points other than
zero (Fig. 5). As a consequence, the drug concentration
would be underestimated if the data were baseline cor-
rected. When multiple covariates and correlations have
been added to the model, it is possible that initial signifi-
cant relations have become redundant and hence can be
removed from the model. It was therefore checked whether
the model could be reduced. Removing any relations
resulted in an increase in OFV, and thus all relations were
still significant. Removing body weight from both CL/
F and V/F increased OFV less than removing body weight
from only one of these parameters, which could be due to the
fact that there is a correlation between the two parameters.
The population pharmacokinetic parameters estimated
with nonlinear mixed-effect modelling for single and
multiple doses of FE 999049 are similar. In the modelling
of single-dose data, CL/F and V/F for a 65 kg woman were
found to be 0.430 L/h and 28.0 L, respectively [2], with a
resulting terminal half-life of 45 h. In this trial, CL/F was
0.423 L/h and V/F was 24.3 L. By incorporating the
inhibin B dynamics into the model, and suppressing the
endogenous FSH contribution instead of letting the FSH
baseline be constant throughout the trial, V/F increased
from 18.9 to 24.3 L, suggesting that without proper esti-
mation of endogenous FSH levels over time a bias in V/
F may be obtained. The terminal half-life in the current
analysis was estimated to be 40 h, thus slightly shorter than
the 45 h reported after single-dose administration. The
phenomenon of shorter half-life after repeated subcuta-
neous dosing compared with single administration was also
observed using NCA-based methods for analysing different
FE 999049 datasets, but could not be further explained [3].
The CL/F for other rFSH products has been found to be
0.99 L/h [3] and 0.71 L/h [9]; thus, our estimated CL/F for
FE 999049 is consistently lower. Furthermore, the terminal
half-life of FE 999049 is longer than reported values in the
literature for repeated subcutaneous dosing of rFSH prod-
ucts, which is approximately 24 h [3, 10]. In the same
studies, a longer terminal half-life has been reported after
single subcutaneous dosing (34.5 [3] and 27 h [10]). One
study [11] found a terminal half-life of 59 h after single
subcutaneous dosing of 115 IU rFSH; however, they noted
that the estimate was not reliable since the low dose only
gave a concentration slightly over baseline.
This work shows that when subjects have measurable
endogenous FSH levels, total FSH concentration is affec-
ted, and the endogenous FSH level varies over time as a
consequence of the feedback from ovarian hormones. If not
accounting for this in the model, the pharmacokinetic
parameter estimates can be biased. The inclusion of
endogenous hormones in the model might be even more
important in the target patient group since they are likely to
have higher endogenous FSH baseline levels as they will
not be pituitary downregulated or suppressed. In addition,
the variation in endogenous FSH levels over time could be
very different between patients due to their different types
Fig. 5 Individual hormone
concentration profiles over time.
The broken blue line indicates
the observed endogenous FSH
baseline level when assuming it
to be constant throughout the
trial, and the solid blue line is
the model-predicted
endogenous FSH level when
accounting for the suppression
caused by the observed inhibin
B levels (purple line) over time,
as identified by the model. The




Population PK and Endogenous FSH Levels After Multiple Dosing of FE 999049 171
of infertility, which might affect the reproductive hormone
dynamics differently. Characterising the endogenous FSH
level and considering the hormone dynamics is therefore
important as it could have clinical relevance for the dose
needed.
In summary, this early characterisation of FE 999049
population pharmacokinetics after repeated dosing is in
line with previously reported findings of rhFSH population
pharmacokinetics after single-dose administration. The
results provide a basis for study design and data evaluation
considerations in the future development of rFSH products.
The standard method of baseline-correcting data for rFSH
products has been questioned since the model indicates that
endogenous FSH significantly affects the total FSH con-
centration and varies over time.
5 Conclusions
The multiple-dose FE 999049 population pharmacokinet-
ics were in agreement with results obtained after single-
dose administration [2]. It was confirmed that after repe-
ated drug administration, FE 999049 exposure also appears
lower in females with a higher body weight. These findings
add to the evidence of body weight being an important
factor in designing individualised dosing schemes.
This analysis indicates that the inclusion of endogenous
FSH levels and quantifying the influence of the reproduc-
tive hormone dynamics at the endogenous FSH level over
time may well be essential for proper estimation of the
pharmacokinetic parameters for FSH preparations. The
standard method of baseline-correcting data does not
account for a variation during the trial and could poten-
tially cause an underestimation of serum drug concentra-
tion and hence inaccurate parameter estimation.
To better explore and link the time-varying impact of
inhibin B on endogenous FSH levels, a more mechanistic
modelling approach may be warranted for including indi-
rect delayed response and hormone feedback mechanisms
in a pharmacokinetic–pharmacodynamic model, and
simultaneously quantifying the inhibin B response to
rhFSH stimulation. The relevance of endogenous hormone
levels should also be related to other pharmacodynamic
and clinical endpoints in order to establish its significance.
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